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cent bands corresponding to BNP and ANP were quantified in densitometric units. 
Results: mRNA expression for both BNP and ANP increased significantly in untreated 
HF dogs compared to NL. Treatment with the CSD reduced mRNA expression of both 
BNP and ANP to near NL levels, Data are shown in the table. 
Conclusions: In dogs with HI:, long-term therapy with the Acorn CSD is associated with 
reduced mRNA expression of both BNP and ANP. These results support earlier findings 
that benefits of the CSD in HF are largely mediated through prevention of myocardial 
stretch. 
Normal HF Untreated HF + CSD 
BNP 2 .7+0.4  5.5+0.2* 3.1 +0.6  
ANP 1.5+0.1 2 ,4+0.1"  2.0+0.1 
*=P<0.05 vs. Normal. Based on ANOVA followed by Student-Neuman-Keuls test 
1061-159 Presentation of Acute Decompensated Congestive 
Heart Failure in African-Americans and Their Response 
to Treatment With Nesiritide 
CIvde W. Yancv, University of Texas Southwestern Medical Center, Dallas, Texas. 
Baekoround: There are often racially based differences in response to cardiovascular 
medications and in disease presentation. Nesiritide (B-type natriuretic peptide) is a newly 
available agent that in clinical trials was shown to: reduce preload and aftedoad, improve 
symptoms, promote natriuresis, and blunt sympathetic and renin-angiotensin-aldoster- 
one axis activation in acutely decompensatod congestive heart failure (CHF) patients. 
M~rthods: To determine the baseline characteristics and hemodynamic and clinical 
effects of nesidtide in African-American (AA) patients, data from the AA patients in a 
large randomized controlled trial (VMAC) of patients with decompensated CHF was ana- 
lyzed. All patients could receive standard therapy, including iV diuretics, dobutamine, and 
dopamine at their physician's discretion. 
Results: in VMAC, 119/489 (24%) of treated patients were AA. Compared to non-AA, the 
primary etiology of chronic cardiomyopathy (CM) in AA patients was more often nonis- 
chemic (59% vs. 31%, respectively, p < 0.001). More AA had hypertensive CM vs. non- 
AA and had a history of hypertension (p < 0.001). Compared to non-AA patients, AA pre- 
sented less frequently with rales (62% [AA] vs. 77% [non-AA], p = 0.002), but more com- 
monly had an $4 (29% [AA] vs. 19% [non-AA], p = 0.04) and hepatomogaly (48% [AA] 
vs. 35% [non-AA], p = 0.018). Baseline NYHA class and ejection fraction were similar in 
AA and non-AA. Like non.AA patients, AA patients who received standard care + nesirit- 
ide (n = 30) had greater reductions in PCWP than those who received standard care + 
placebo (n = 14) at every time point from 15 minutes to 3 hours (p _< 0.05 for all points). At 
3 hours, the primary endpoint, PCWP decreased by -5.9 mmHg in the nesiritide (+ stan- 
dard care) vs. -0.6 mmHg in the placebo (+ standard care) groups (p = 0.001). The per- 
centage of patients with improved dyspnea was 88% (AA) vs. 65% (non-AA) (p = 0.028). 
Conclusions: AA patients have a greater preponderance of hypertensive cardiomyopa- 
thy and evidence of teft ventdoular noncompliance. The AA population within the VMAC 
study had similar improvements over standard care in hemodyamics and symptoms 
when treated with nesiritide as compared to the non-hA VMAC patients. 
1061-160 Effects of the Creation of Arteriovenous Shunt for 
Hemodialysis on Cardiac Function and Natriuretic 
Peptide Levels in Chronic Renal Failure 
Yoshio Iwashima. Takeshi Horio, Yoichi Takami, Takashi Inenaga, Toshio Ogihara, Yuhei 
Kawano, Geriatric Medicine, Osaka University Medical School, Suita, Japan, National 
Cardiovascular Center, Suita, Japan. 
Background: Heart failure is caused occasionally by the creation of vascular access for 
hemodialysis. However, the effect of arteriovenous (AV) shunt on cardiac function has 
not been fully elucidated. This study investigated the serial changes in cardiac function 
and hormonal evels by the AV shunt operation. Methods: Sixteen patients with end stage 
renal disease underwent echocardiographic studies before and 3, 7, and 14 days after 
the AV shunt operation. Plasma atrial natriuretic peptide (ANP) and brain natriuetic pep- 
tide (BNP) concentrations were measured before and 1,3, 6, 10, and 14 days after the 
operation. Results: The creation of AV shunt produced significant elevations of left ven- 
tdcular end-diastolic diameter (+4% at 7 days, P=0.005), left ventricular end-diastolic vol- 
ume (+10% at 7 days, P=0.006), fractional shortening (+8% at 7 days, P=0.001), and 
cardiac output (+15% at 7 days, P=0.01). In transmitral flow by Doppler echocardio- 
graphy, the deceleration time of the early diastolic filling wave shortened (-12% at 14 
days, P=0.00t) and the ratio of the peak velocity of early diastolic to atrial filling (E/A) 
increased (+18% at 14 days, P=0.004). That is, the creation of AV shunt induced the 
restrictive impairment in LV diastolic function. Blood pressure showed a tendency to 
decrease and heart rate did not change significantly through the study, Both ANP and 
BNP increased after the operation, and the maximal increases were observed after 10 
days (ANP: +48%, BNP: +68%). In the relationship between cardiac function and hor- 
monal response, the increase in cardiac output was associated with the elevation of ANP 
(r=0.61, P=0.01), but not BNP. On the other hand, the increase in E/A was correlated 
only with BNP elevation (r=0.60, P=0.01). Therefore, the stimulation of ANP and BNP 
secretions was differently regulated by other hemodynamic factors. Conclusion: This is 
the first report that shows the serial changes in cardiac function and hormonal levels after 
the AV shunt operation. Our observations indicate that the creation of AV shunt has sig- 
nificant effects on cardiac performance and that ANP release is induced by volume load- 
ing, but BNP release is stimulated by left ventricular diastolic dysfunction. 
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1062MP-121 Reverse Remodeling Following Long-Term Carvedilol 
Therapy Is Associated With Improvement in Survival: 
The Stanford Carvedllol Echocardiographic Regis t ry  
W.H, Wilson Tano, Mary S. Larson, Randal~ H. Vagelos, Lisa Prikazsky, Bob S. Hu, 
Michael B. Fowler, Stanford University, Stanford, California. 
Background: Beta-blocker therapy reverses the process of ventricular remodeling and 
reduces mortality in patients with heart failure. However, direct association between 
reverse remodeling and improvement in survival has not been demonstrated. Few clini- 
cal parameters have been shown to provide prognostic information during ongoing head 
failure treatment. 
Methods: We prospectively followed 257 patients with chronic heart failure treated with 
carvedilol for over 6 months between 1993-9. Serial echocardiographic assessments of 
left ventdcular ejection fraction (LVEF, n=257) and left ventdcular end-diastolic dimen- 
sions (LVIDd, n=242) were measured at baseline and at 6-12 months ("serial") following 
carvedilol therapy. "Reverse remodeling" was defined as improvement in LVEF _>10% or 
reduction in LVlDd _>10 mm in serial measurements. Clinical end-points were all-cause 
mortality (by clinical records and/or by Social Security Death Index) and transplantation 
(by clinical records) up to May 2001. Comparisons between groups based on echocar- 
diographic criteria (baseline and serial LVEF/LVIDd) were performed using Kaplan-Meier 
survival curves. 
Results: Of the 257 patients studied (mean age 52+13 years, mean LVEF 24.8+8%, 
mean LVlDd 70_+10mm), 127 (49%) had reverse remodeling by LVEF criteria, and 65 out 
of the 242 patients (27%) had reverse remodeling by LVIDd criteria. During a mean fol- 
low-up of 4 years, 53 (20.6%) died or underwent ransplantation. Kaplan-Meier survival 
curves of patients were not significantly different between groups according to baseline 
LVEF (<25% versus _>25%) or LVlDd (<70mm versus _>70mm) measurements; but were 
significantly different at the log-rank test between groups with or without reverse remod- 
eling according to serial LVEF or LVlDd measurements (log-rank ;C 2, p <0.001). 
Conclusion: Baseline LVEF and LVIDd did not predict survival following carvedilol ther- 
apy. However, echocardiographic parameters of reverse remodeling were associated 
with improvement in survival following carvedilol therapy. Serial measurements in such 
parameters during ongoing treatment may therefore provide additional prognostic infor- 
mation for patients with heart failure. 
3:12 p.m. 
1062MP-122 Effects of Valsartan on Left Ventricular Ejection 
Fraction and Diastolic Diameter in Patients With Heart 
Failure: VaI-HeFT Echocardlogrsphic Study 
Mavlene Wona, Lidia Staszewsky, Roberto Latini, Yann-Toog Chiang, Alberto Volpi, 
Christer Hoglund, Jay N. Cohn, for the VaI-HeFT Investigators, West LAVA Medica/ 
Center, Los Angeles, California, Istituto Mario Negri, Milano, Italy. 
Objective: To evaluate the effect of the angiotensin receptor blocker valsartan on left ven- 
tdcular (LV) structure and function when added to standard head failure (HF) therapy. 
Methods: At 302 multi-national sites, 5010 pts in NYHA class II to IV HF on stable ther- 
apy which could include ACE inhibitor and betablocker were randomized to valsartan (V) 
and placebo (P) groups and followed for a mean duration of 22.4 mos. Serial echocardio- 
graphic (echo) measurements of ejection fraction (EF) and LV internal diastolic diameter 
(LVID) were recorded. Reproducibility calculated to 90% power at 5% significance 
revealed detectable differences of 0,86% for EF and 0.09 cm for LVID. Mean group 
changes from baseline over time were compared. 
Results: Baseline EF and LVID for V and P groups were similar: 26.60 vs 26.87 (%); 
3.64 vs 3.66 (cm/m2). Consistent, significant increase in EF and decrease in LVID began 
at 4 mos, reached a plateau by 1 year, and persisted to 2 years in V compared to P pts. 
Similar trends were seen in males and females, and pts <65 and >65 years, Racial differ- 
ences in response to V were suggested, but the number of black pts was small. 
Conclusions: VaI-HeFT provided a large HF pts recruitment and multiple sequential 
echocardiograms for studying effects of V on echo measurements. The data demon- 
strated that V treated pts had a decrease in LV size and increase in systolic function that 
began to develop by 4 mos and continued for at least 2 years.* p<0.001; § p=0.032; # 
p=0,034. ANCOVA controlling for center and baseline. 
Interval 4 mos 12 mos 18 mos 24 mos 
n=4,556 n=4,014 n=3,018 n=1,991 
EF V 2.73* 4.12" 4.49* 4.50# 
P 2.02 2.82 3.21 3.66 
LVIDd/BSA V -0.07" -0.09* -0.12" -0.10§ 
P -0.03 -0.05 -0.05 -0.06 
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